Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors

Core Insights - Terns Pharmaceuticals has appointed Heather Turner, J.D., to its Board of Directors, effective immediately, while Ann E. Taylor, M.D., is stepping down after over three years of service [1][2] Company Overview - Terns Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing small-molecule product candidates targeting serious diseases, including oncology and obesity [3] - The company's pipeline includes three clinical-stage development programs: an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, and a THR-β agonist, along with a preclinical GIPR modulator discovery effort [3] Leadership Changes - Heather Turner brings 25 years of biotechnology experience, including her recent role as CEO of Carmot Therapeutics, which was acquired by Roche for $3.1 billion [2] - The CEO of Terns, Amy Burroughs, expressed confidence in Turner's ability to contribute to the company's strategic decisions and growth [2]